Enanta Pharmaceuticals

ENTA

Market cap $177M

Overview Fund Activity

8.28 USD

-0.38

4.39%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

8.28

0.00

0%

1 day

-4.39%

5 days

-6.44%

1 month

20.7%

3 months

11.74%

6 months

13.89%

Year to date

48.12%

1 year

-32.08%

5 years

-82.56%

10 years

-80.16%

About: Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Employees: 131

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

4,444% more call options, than puts

Call options by funds: $409K | Put options by funds: $9K

35% more capital invested

Capital invested by funds: $103M [Q1] → $139M (+$36.4M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

1.17% less ownership

Funds ownership: 87.32% [Q1] → 86.15% (-1.17%) [Q2]

4% less funds holding

Funds holding: 109 [Q1] → 105 (-4) [Q2]

21% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 43

24% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 17

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$20

142% upside

Avg. target

$23

178% upside

High target

$25

202% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

WestPark Capital Ed Arce	$24	Buy Initiated	2 Sep 2025
JMP Securities Roy Buchanan	$25	Market Outperform Maintained	12 Aug 2025
HC Wainwright & Co. Brandon Folkes	$20	Buy Assumed	28 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ENTA published over the past 30 days

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. “The entire Enanta team mourns the loss of Paul, our colleague and friend,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “Since joining the Company more than two decades ago, Paul's leadership and generosity of spirit have been at the core of Enan.

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

Enanta Pharmaceuticals to Participate in September Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in three investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside Chat on Wednesday, September 3, 2025 at 8:35 a.m. ET H.C. Wainwright 27th Annual Global Investment Conference: Fireside Chat on Tuesda.

Enanta Pharmaceuticals to Participate in September Investor Conferences

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '26.

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

Zacks Investment Research

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to a loss of $1.07 per share a year ago.

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

WATERTOWN, Mass.--(BUSINESS WIRE)-- #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2025. “This past quarter we continued to make steady progress across our pipeline, marked by the completion of enrollment in the RSVHR trial, a proof-of-concept study of zelicapavir in high-risk adults infected w.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, August 12, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. “HCW@Home” series. A live webcast of the event will be accessible by visiting the “Events and Presentations” section.

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, July 22 at 1:30 p.m. ET as part of Baird's Biotech Discovery Series. A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page.

Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved as the only eight-week treatment for adults and pediatric patients three.

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the “Even.

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 2.

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

See News Rankings

Charts implemented using Lightweight Charts™